The DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab brand, founded in 2010 (United States), from 496 sister brands and 17478 competing brands. DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab is a brand of BRISTOL-MYERS SQUIBB COMPANY, listed on the stock exchange of New York. DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab belongs to the Drug Manufacturers business sector.

DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab is a brand of BRISTOL-MYERS SQUIBB COMPANY (BMY) Sustainability

Here is the evolution of interest in BRISTOL-MYERS SQUIBB COMPANY "sustainability" criteria around the world over the past five years. The graph shows the evolution of the search rate over time, where the value 100 indicates the week with the most searches.
What is the brand's web response on its sustainability: Result of Google's query: "DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab sustainability"
: Sustainability -> Share price